METHOD FOR INCREASING GENE THERAPY EFFICACY AND SAFETY

Information

  • Research Project
  • 6486229
  • ApplicationId
    6486229
  • Core Project Number
    R43CA090097
  • Full Project Number
    1R43CA090097-01A1
  • Serial Number
    90097
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2002 - 22 years ago
  • Project End Date
    12/31/2002 - 21 years ago
  • Program Officer Name
    DUGLAS-TABOR, YVONNE
  • Budget Start Date
    8/1/2002 - 22 years ago
  • Budget End Date
    12/31/2002 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    8/1/2002 - 22 years ago

METHOD FOR INCREASING GENE THERAPY EFFICACY AND SAFETY

DESCRIPTION (provided by the applicant): The aim of this proposal is to develop a non-myeloablative conditioning protocol with increased safety and efficacy for the induction of specific immune tolerance to genetically modified cells. Potential applications of gene therapy in the treatment of genetic and autoimmune disorders are widespread, but progress has suffered from a severe reduction in efficacy due to immune reactions raised against therapeutic transgene products. Induction of specific immune tolerance through mixed hematopoietic chimerism is an established methodology that can effectively re-educate the immune system to eliminate immune rejection. To achieve engraftment of allogeneic stem cells, conditioning requirements are associated with toxicities, and graft-versus-host disease is a common side effect. Studies have shown that molecular chimerism can be used to induce tolerance. Our preliminary data suggest that specific immune tolerance can be induced to a single immunogenic protein expressed on autologous cells, and that conditioning requirements for transplantation of molecularly modified autologous cells are less than those required for allogeneic transplants. We believe that the effectiveness of gene therapy can be greatly improved by inducing specific immune tolerance to foreign proteins to be transferred and that this can be accomplished using non-toxic protocols.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOTRANSPLANT, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BOSTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02129
  • Organization District
    UNITED STATES